Getting to sleep when you have Osteoarthritis – Can Cognitive Behavioural Therapy Help?
Recently research by Michael
V. Vitiello at the University of Washington has shown that cognitive behavioural therapy (CBT) improve
sleep in people who have osteoarthritis. The study involved 51 participants who
were randomly assigned to either a control group or a CBT group. The CBT group
received 8 two-hour classes of CBT in small groups (4-8 subjects) whilst the
control group received generic wellness classes. After the intervention the CBT
group were shown to have significantly improved sleep quality. Interestingly
the improvement in sleep was also associated with an improvement in pain.
Cognitive Behavioural
Therapy is a form of psychotherapy designed to help change the way people think
and behave. Unlike many other psychotherapies that focus on the causes of
distress, CBT takes a problem solving approach that focuses on ways to improve
your psychological state.
Osteoarthritis (OA) is a
condition whereby there is an inflammation of the joint caused by a
degeneration of the cartilage that lines the joint. As the cartilage degenerates
there can also be changes in the bony surfaces of the joint which can lead to
pain and joint dysfunction. Otherwise known as the “wear and tear arthritis” OA
is thought to affect an estimated 8.5 million people in the UK. Most commonly, osteoarthritis develops over the age
of 50 and is more common in men. Osteoarthritis is more common if there has
been some kind of injury to one of the joints. One of the common symptoms of
osteoarthritis is night pain which can have a big impact on quality of live.
Acupuncture may change the brain
Acupuncture is a technique
that involves inserting and manipulating very fine needles into specific points
on the body with the aim of relieving pain. Chinese Acupuncture has been used
to treat pain for thousands of years in the Far East. Chinese Acupuncture is increasingly being used today but as demand for
this therapy increases, there is also an increasing need to try and understand
if and how the therapy works. By understanding the therapeutic effect of Chinese
acupuncture it may be possible for scientists to develop more effective
protocols that will be more acceptable within mainstream medicine.
Recently, a research team
from the University of Michican used a brain imaging technique to try and understand how activity in
the brain changes during Chinese Acupuncture. Twenty women who had Fibromyalgia
related pain for at least 1 year were recruited to the study. Within this group
half the women had the real acupuncture over an 8 week period whilst half
received a control intervention. A PET scan was applied before and after the
study to analyse the binding availability of different pain receptors in the
brain.
Whilst both groups
experienced a reduction in pain, the brain activity changes were different.
Most notably, there was a change in the binding availability of opioid pain
receptors in the Chinese Acupuncture group. Opioids are thought to work by
activating these types of receptors and so a change in the binding availability
of these types of receptors may alter the way these drugs work. Whilst more
research needs to be done in this area, this small study does hintthat acupuncture may have a real
physiological effect on pain receptor in the brain.
Mirrors used for phantom limb pain
Phantom limb pain is a chronic condition whereby sufferers experience pain from the site of the amputated limb. Approximately 50-80% of amputees suffer from some degree of phantom limb pain and it occurs independently of gender, side of amputation and age. Phantom limb pain can be difficult to control with drugs which has led researchers to look for other treatment possibilities. One treatment that has been gaining increased recognition in the last 15 years is mirror therapy. Mirror therapy quite simple involves trying to trick the brain into thinking that the missing limb is not actually missing and can be moved. For some people this illusion can provide a significant reduction in phantom limb pain. Quite why this therapy works is still not clear but there is growing evidence to suggest that the therapy normalises abnormal activity in part of the brain that controls and senses the missing limb. One reason why this therapy is so exciting is because unlike drugs it should not have any side effects.
Acupuncture, manual therapy and exercises to be offered for low back pain
For the first time the National Institute for Health and Clinical Excellence has backed the use of acupuncture, manual therapy and exercises as treatment options for persistent low back pain. The reason why 3 therapies are being offered is because whilst research has shown that acupuncture, manual therapy and exercise can be beneficial for persistent back pain it is not clear if one therapy is superior to the other.
Anyone with persistent back pain for over 9 weeks will be given the normal advice and medication options. In addition, people will be able to choose from a course of acupuncture, manual therapy or exercise. Low back pain is a widespread problem in the UK with an estimated 2.5 million people visiting their GP with the condition
Opioids may not be as addictive as once thought
Opioids have been
successfully used for pain relief for many years. One of the concerns about
opioid prescription has been opioid addiction and abuse. Indeed, some areas of
the media have suggested that increased opioid abuse may be caused by a greater
numbers of patients being prescribed opioids for chronic pain management. In
contrast to these reports, recent evidence suggests that the problem may not be
as serious as once thought. In an extensive review of research papers (which
included 17 studies of people being treated with opioids for chronic pain) opioid
abuse was reported in 0.4% of patients. This finding is particularly important
for doctors considering opioid prescription, who can be reassured that only a
very small percentage of chronic pain patients are likely to be at risk of
opioid abuse.
Food and Drug Administration Agency in the USA announces approval of Fibromyalgia drug
Two
world renowned laboratories have announced that a new drug called Savella
(Milnacipran) has been approved by the FDA for the management of Fibromyalgia. Fibromyalgia
(FM or FMS) is a chronic soft tissue disorder characterised by widespread pain
and an increased sensitivity to touch stimuli. Fibromyalgia can occur at any age;
however, it is more common in women between the ages of 20 to 40. Savella is a
selective serotonin and norepeniphrine dual reuptake inhibitor (SSRI). A
serotonin and norepinephrine dual reuptake inhibitor (SSRI) is a type of
antidepressant that reduces the reuptake of serotonin and norepinephrine, in
order to boost their levels in the brain. The approval of Savella comes after
phase III clinical trials involving over 2000 Fibromyalgia patients. Patients taking Savella doses of 100 mg/day and 200 mg/day demonstrated clinically significant
improvements in their global assessment of pain and daily physical function.
Weights may be better for back pain than Aerobics
Back pain is a major cause of disability in the UK. There are a wide variety of treatments available for back pain and there has been a growing interest in working out what is the most effective treatment. New research from the University of Alberta and University of Regina has suggested that weight training is more effective to ease lower back pain than other forms of exercise such as jogging. In the study, chronic back pain sufferers were assigned to a 16 week period of aerobic training (walking on a treadmill/jogging) or resistance training (lifting dumbbells, barbells and other load-bearing exercise equipment). Interestingly, the aerobic training group experienced a 12% improvement in pain and function levels, whilst the resistance training group had a 60% improvement.
Pain may cause Arthritis: New Study
New research from the Journal of Arthritis and Rheumatism
has reported evidence to suggest that as well as being a symptom of
osteoarthritis, pain may also cause arthritis. Researchers found that some of the pathways carrying pain
signals also transferred inflammation from arthritic joints to the spine and
back again. In the experiment, the researchers genetically engineered a mouse
where they could turn up and turn down the production of a chemical (IL-1β )
known to be involved in inflammation. Most notably, they found that increasing
production of IL-1β at the peripheral joint caused higher levels of IL-1β to be
produced in the spinal cord. This finding is important as it may help researchers
develop new drug targets to try and prevent the spread of inflammation.
Novel nerve stimulation helps chronic headaches
Recently, research has shown that a new form of electrical stimulation may be effective in the management of a chronic headache disorder. The study was conducted by the University of California, San Francisco and the NationalHospital for Neurology and Neurosurgery in London and involved six subjects suffering from a condition called hemicrania continua (a rare headache disorder). Each subject had a matchstick sized battery operated electrode (bion) implanted near the occipital nerve in the back of the neck. Researchers found that in the month after implantation of the bion, five of the six patients reported significant reduction in headache symptoms. Similar results were reported in 2007 by two other research teams studying patients with chronic cluster headaches.
New drug for Rheumatoid Arthritis
Recent research led by Professor Paul Emery at LeedsUniversity showed that a monthly injection of a drug called tocilizumab can rapidly diminish the painful and debilitating effects of Rheumatoid Arthritis. In trials involving over 1000 subjects, tocilizumab plus methotrexate halted the condition in 47% of patients, compared to only 8% when methotrexate was taken alone. Tocilizumab is thought to work by blocking Interleukin 6 which is a signalling molecule thought to be involved in the development of rheumatoid arthritis. The drug is not yet available as it is awaiting approval from drug regulators in the US and Europe. However, when it does come out it will be sold under the brand name RoActemra by Roche.
The information provided on this website is not intended as specific medical advice and is not a substitute for a professional medical diagnosis or treatment. Read our
Medical Advice Notice.